NICE confirms limits on Alimta for lung cancer
This article was originally published in Scrip
Executive Summary
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.
You may also be interested in...
Cervarix link to UK girl's death "unlikely"
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Generic Topamax launched in European markets
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
HRA's Rome office to launch morning-after pill in difficult market
EllaOne (ulipristal acetate), HRA Pharma's emergency contraceptive, was approved for EU marketing in May under the centralised procedure, and the company is building a commercial presence throughout Europe to handle its launch.